CASSANDRA GROVER: Open Payments
NPI 1982230959 · ANDERSON, SC. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$864 in 57 payments from 15 companies in 2025. Trend: 2023 $826 · 2024 $709 · 2025 $864
Food & beverage: $864
| Company | Payments | Amount |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | 15 | $188 |
| ABBVIE INC. | 17 | $177 |
| Otsuka America Pharmaceutical, Inc. | 5 | $99 |
| Neurocrine BioSciences, Inc. | 3 | $63 |
| Alkermes, Inc. | 3 | $59 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $55 |
| Lundbeck LLC | 2 | $50 |
| Axsome Therapeutics, Inc. | 2 | $39 |
| Noven Therapeutics, LLC | 1 | $22 |
| Bausch Health US, LLC | 1 | $22 |
Products named: TRINTELLIX, VRAYLAR, REXULTI, INGREZZA, CAPLYTA, Auvelity, Xelstrym, APLENZIN.
Industry payments across SC — which companies pay providers there.
